Last reviewed · How we verify
EnvarsusXR
Calcineurin inhibitor
Calcineurin inhibitor Used for Organ transplantation.
At a glance
| Generic name | EnvarsusXR |
|---|---|
| Also known as | Immunosuppression |
| Sponsor | Albert Einstein Healthcare Network |
| Drug class | Calcineurin inhibitor |
| Target | Calcineurin |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
EnvarsusXR is an extended-release formulation of tacrolimus, which works by inhibiting calcineurin, a protein phosphatase involved in the activation of T-lymphocytes.
Approved indications
- Organ transplantation
Common side effects
- Diarrhea
- Nausea
- Headache
Key clinical trials
- Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR (PHASE4)
- Evaluate the Clinical Benefits of EnvarsusXR in Post Liver Transplant (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EnvarsusXR CI brief — competitive landscape report
- EnvarsusXR updates RSS · CI watch RSS
- Albert Einstein Healthcare Network portfolio CI